Robert Gaudette, PharmD/MBA Candidate 2016

Pharmacists should reconsider recommending toxic chemotherapy for cancer palliation because it may significantly worsen terminal cancer patients' quality of life near death.

A study evaluating the cardiovascular safety of Merck's type 2 diabetes drug sitagliptin determined the dipeptidyl peptidase-4 inhibitor does not increase the risk for heart failure hospitalization.

Pharmacists know changes in vitamin K intake can drastically alter INR values in patients taking warfarin.